| Literature DB >> 34632341 |
Adnan S Hussaini1, Navin R Prasad2, Edina Paal3,4, Eshetu A Tefera5, Sonya Malekzadeh1,3, Jessica H Maxwell1,3.
Abstract
OBJECTIVE: Salivary gland tumors account for 6%-8% of head and neck neoplasms with the parotid gland as the most common primary site. Pleomorphic adenomas (PA) are considered the most common benign parotid gland neoplasms, followed by Warthin tumors (WT). The goal of this study was to investigate the distribution of parotid gland neoplasms among a United States veteran population.Entities:
Keywords: Head and neck cancer; Parotid neoplasm; Pleomorphic adenoma; Tobacco; Veteran; Warthin tumor
Year: 2020 PMID: 34632341 PMCID: PMC8486690 DOI: 10.1016/j.wjorl.2020.05.009
Source DB: PubMed Journal: World J Otorhinolaryngol Head Neck Surg ISSN: 2095-8811
Retrospective studies of pleomorphic adenoma (PA) and Warthin tumor (WT) epidemiology in the parotid gland.
| Study | Country | Time period | Benign parotid neoplasms(N) | PA frequency(%) | WT frequency(%) |
|---|---|---|---|---|---|
| Ethunandan et al, 2002. | England | 1974–1999 | 460 | 59.6 | 32.6 |
| Lukšić et al. | Croatia | 1985–2009 | 383 | 66.8 | 22.8 |
| Christensen et al. | Denmark | 1986–1995 | 433 | 54.0 | 28.0 |
| Gierek et al. | Poland | 1986–2006 | 416 | 75.0 | 24.0 |
| Luers et al. | Germany | 1990–2014 | 1818 | 61.1 | 38.9 |
| Coombe et al. | Australia | 2006–2013 | 77 | 59.7 | 24.6 |
Distribution of parotid neoplasms (2000–2018).
| Histologic type | N | Percentage (%) |
|---|---|---|
| Benign | 122 | 100.0 |
| Warthin tumor | 63 | 51.6 |
| Pleomorphic adenoma | 49 | 40.2 |
| Basal cell adenoma | 2 | 1.6 |
| Lipoma | 7 | 5.7 |
| Myoepithelioma | 1 | 0.8 |
| Malignant | 14 | 100.0 |
| Acinic cell carcinoma | 2 | 14.3 |
| Adenocarcinoma | 1 | 7.1 |
| Basal cell adenocarcinoma | 1 | 7.1 |
| Lymphoma | 4 | 28.6 |
| Mucoepidermoid carcinoma | 3 | 21.4 |
| Salivary duct carcinoma | 1 | 7.1 |
| Squamous cell carcinoma | 2 | 14.3 |
| Indeterminate neoplastic lesions (FNA only) | 5 | 100.0 |
Non-diagnostic and normal FNAs excluded.
Metastatic lesions excluded.
Characteristics of benign parotid neoplasms (2000–2018).
| Bivariate mode | Pleomorphic adenoma (N = 49) | Warthin tumor (N = 63) | |
|---|---|---|---|
| Gender N(%) | 0.0228 | ||
| Female | 11 (22.4) | 4 (6.3) | |
| Male | 38 (77.6) | 59 (93.7) | |
| Age(year, | 60.0 ± 12.9 | 66.8 ± 9.4 | 0.0018 |
| BMI( | 28.3 ± 5.3 | 28.4 ± 5.9 | 0.9189 |
| Race N(%) | 0.3437 | ||
| Asian | 0 | 2 (3.2) | |
| Black | 28 (57.1) | 29 (46.0) | |
| Native American | 0 | 1 (1.6) | |
| Other | 3 (6.1) | 9 (14.3) | |
| White | 18 (36.7) | 22 (34.9) | |
| Tobacco N(%) | 0.0106 | ||
| Current | 13 (26.5) | 34 (54.0) | |
| Former | 19 (38.8) | 18 (28.6) | |
| Never | 17 (34.7) | 11 (17.5) | |
| Surgery N(%) | 0.4373 | ||
| Yes | 36 (73.5) | 42 (66.7) | |
Fig. 1Proportions of neoplasms over time. Absolute numbers of all tumors observed at our institution from 2000 to 2018, as diagnosed on FNA, and when available, surgical pathology. 2010 to 2018, as diagnosed on FNA, and when available, surgical pathology.
Fig. 2Incidence of Warthin tumor compared to all parotid neoplasms. Relative incidence of WT (diamond) compared to all other neoplasms (triangle) by year. Trend line indicates an increase in incidence of WT (P = 0.0422).
Fig. 3Rates of tobacco use from 2000 to 2018. Incidence in tobacco use across four distinct time periods.